← Back to Search

Cancer Vaccine

Trial of PalloV-CC in Colon Cancer

Phase 1
Waitlist Available
Led By George Peoples, MD
Research Sponsored by George E. Peoples
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year for all 4 cohorts to enroll and undergo treatment.
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new vaccine called PalloV-CC in patients with colon cancer. The vaccine aims to improve the body's immune response to the cancer. Researchers will observe changes in the tumor environment to see how well it works.

Eligible Conditions
  • Colon Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year for all 4 cohorts to enroll and undergo treatment.
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for all 4 cohorts to enroll and undergo treatment. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Primary Immunologic Endpoint-Overall Immunoscore of the tumor microenvironment
Primary Immunologic Endpoint-Per Dosing Cohort Immunoscore of the tumor microenvironment
Primary Safety Endpoint-Overall number of participants with treatment-related adverse events as assessed by CTCAE v4.0.
+1 more
Secondary study objectives
Secondary Endpoint-CD4+ and regulatory T cells expression comparison within the Tumor Microenvironment
Secondary Endpoint-Effect Tumor Microenvironment measured via Immunoscore
Secondary Endpoint-Immunologic comparison of evaluations of tumor microenvironment
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups
Experimental Treatment
Group I: 8x10^8 particles of PalloV-CCExperimental Treatment1 Intervention
Intradermal injection of PalloV-CC weekly x 4 weekly
Group II: 4x10^8 particles of PalloV-CCExperimental Treatment1 Intervention
Intradermal injection of PalloV-CC weekly x 4 weekly
Group III: 2x10^8 particles of PalloV-CCExperimental Treatment1 Intervention
Intradermal injection of PalloV-CC weekly x 4 weekly
Group IV: 1x10^8 particles of PalloV-CCExperimental Treatment1 Intervention
Intradermal injection of PalloV-CC weekly x 4 weekly
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PalloV-CC
2019
Completed Phase 1
~30

Find a Location

Who is running the clinical trial?

George E. PeoplesLead Sponsor
1 Previous Clinical Trials
275 Total Patients Enrolled
PalloV, LLCUNKNOWN
George Peoples, MDPrincipal InvestigatorCancer Insight
1 Previous Clinical Trials
26 Total Patients Enrolled
George Peoples, MD, FACSPrincipal InvestigatorLumaBridge
~4 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top